Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.

Ahead of the event, analysts expect Cencora to report a profit of $3.50 per share, up 6.7% from $3.28 in the year-ago quarter.The company has consistently surpassed Wall Street’s adjusted EPS ...

Cencora (NYSE:COR – Get Free Report) had its price objective increased by analysts at Wells Fargo & Company from $251.00 to $274.00 in a report released on Friday,Benzinga reports.The firm ...

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.

It has been about a month since the last earnings report for Cencora (COR). Shares have added about 3.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

PharmaLex is now part of Cencora, a leading global pharmaceutical solutions organization centered on improving lives around the world. PharmaLex adds to Cencora’s expanding suite of pharma solutions ...

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora’s results and ...

But on the bright side, you can make far more than 100% on a really good stock. Long term Cencora, Inc. (NYSE:COR) shareholders would be well aware of this, since the stock is up 156% in five years.

Baird raised the firm’s price target on Cencora (COR) to $307 from $305 and keeps an Outperform rating on the shares. The firm noted it was another beat and raise quarter. Published first on ...